Patent US4601168A successfully refreshed from Google Patents.
Patent US4703036A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4703036A Expired / Lapsed US ⏱️ 0.0 years remaining

Peptide-aldehydes, process for the preparation thereof and pharmaceutical compositions containing the same

Assignee: Teva Hungary Pharmaceutical Marketing PLC
•
Filing: 1985-12-20
•
Granted: 1987-10-27
•
Expires: 2005-12-20
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention relates to new peptide-aldehydes and a process for the preparation thereof, furthermore to pharmaceutical compositions containing the same. According to a feature of the present invention there are provided new peptide-aldehyde derivatives corresponding to the general formula (I) <IMAGE> (I) wherein R1 represents hydrogen or C1-6 alkyl group, R2 stands for C1-6 alkyl group, furthermore R1 and R2 are linked to the amino group of the Xxx alpha-amino acid, Xxx represents a D-phenylalanine residue or a D-alpha-amino acid group having in the side chain a C1-4 alkyl group, Pro stands for L-proline residue, Yyy stands for L-, D- or DL-arginine residue and A represents an acid residue. The new peptide-aldehyde derivatives of the invention possess valuable anticoagulant activity.

Inventors

  • 👤 Sandor Bajusz
  • 👤 Erzsbet Szell nee Hasenohrl
  • 👤 Daniel Bagdy
  • 👤 Eva Barabas
  • 👤 Mariann Dioszegi
  • 👤 Zsuzsa Fittler
  • 👤 Ferencz Jozsa
  • 👤 Gyula Horvath
  • 👤 Eva Tomori nee Jozst

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-05 15:45
CPC Classifications
C; C07; C07K; C07K5/00; C07K5/04; C07K5/06; C07K5/06008; C07K5/06078; Y; Y02; Y02P; Y02P20/00; Y02P20/50; Y02P20/55

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 72 words
A peptide-aldehyde derivative having the formula (I) ##STR3## wherein R 1 represents hydrogen or C 1-6 alkyl group, R 2 stands for C 1-6 alkyl group, furthermore R 1 and R 2 are linked to the amino group of the Xxx alpha amino acid, Xxx represents a D-phenylalanine residue or a D-alloisoleucine residue, Pro stands for L-proline residue, Yyy stands for L-, D- or DL-arginine residue, and A represents an acid residue.
Claim 2
Dependent Claim 72 words
A peptide-aldehyde derivative having the formula (I) ##STR3## wherein R 1 represents hydrogen or C 1-6 alkyl group, R 2 stands for C 1-6 alkyl group, furthermore R 1 and R 2 are linked to the amino group of the Xxx alpha amino acid, Xxx represents a D-phenylalanine residue or a D-alloisoleucine residue, Pro stands for L-proline residue, Yyy stands for L-, D- or DL-arginine residue, and A represents an acid residue.
Claim 3
Dependent Claim 18 words
A compound according to claim 1, wherein R 1 is hydrogen and R 2 is a methyl group.
Claim 4
Dependent Claim 15 words
A compound according to claim 1, wherein R 1 and R 2 are methyl groups.
Claim 5
Dependent Claim 15 words
A compound of the formula (I) of claim 1, wherein Xxx is a D-phenylalanine residue.
Claim 6
Dependent Claim 15 words
A compound of the formula (I) of claim 1, wherein Yyy is an L-arginine residue.
Claim 7
Dependent Claim 29 words
A compound of formula (I) as defined in claim 1 selected from the group consisting of N-methyl-D-phenylalanyl-L-prolyl-L-arginine-aldehyde sulfate, N,N-dimethyl-D-phenylalanyl-L-prolyl-L-arginine-aldehyde sulfate, N-ethyl-D-phenylalanyl-L-prolyl-L-arginine-aldehyde sulfate, N-isobutyl-D-phenylalanyl-L-prolyl-L-arginine-aldehyde sulfate, N-methyl-D-alloisoleucyl-L-prolyl-L-arginine-aldehyde sulfate and N-n-hexyl-D-phenylalanyl-L-prolyl-L-arginine-aldehyde sulfate.
Claim 8
Dependent Claim 31 words
A pharmaceutical composition having anticoagulant activity, which comprises as active ingredient at least one compound of formula (I) as defined in claim 1 in admixture with one or more pharmaceutical carriers.
Claim 9
Dependent Claim 37 words
A method of inhibiting blood coagulation in a mammalian subject which comprises the step of administering to said mammalian subject a therapeutically effective amount of the aldehyde salt of the Formula (I) as defined in claim 1.
Claim 10
Dependent Claim 25 words
The method of inhibiting blood coagulation defined in claim 8 wherein the aldehyde salt of the Formula (I) is orally administered to the mammalian subject.
Claim 11
Dependent Claim 25 words
The method of inhibiting blood coagulation defined in claim 8 wherein the aldehyde salt of the Formula (I) is intravenously administered to the mammalian subject.

References Cited (Backward Citations)

US4399065A Cited
US4478745A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1990-10-26 1991-04-27 1991-10-27 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1994-10-26 1995-04-27 1995-10-27 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1998-10-26 1999-04-27 1999-10-27 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag